<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Breast cancer risk prediction tools</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Breast cancer risk prediction tools</h1>
<div class="graphic"><div class="figure"><div class="ttl">Breast cancer risk prediction tools</div><div class="cntnt"><table cellspacing="0"><colgroup width="25%"></colgroup> <colgroup width="75%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Model</td> <td class="subtitle1">Characteristics and limitations</td> </tr> <tr> <td class="divider_bottom" rowspan="3">Gail model 2 <span class="nowrap_whitespace">(BRCAT)<sup>[1]</sup></span></td> <td>Considers nongenetic risk factors such as age at menarche, first term birth, and biopsy history, including atypical hyperplasia. Not appropriate for females with DCIS, LCIS, prior chest radiation due to Hodgkin lymphoma, or for females with <em>BRCA 1/2</em> mutations.</td> </tr> <tr> <td>Does not consider family history beyond first-degree relatives with breast cancer. It does not factor in any other cancers or any paternal relatives with cancer.</td> </tr> <tr class="divider_bottom"> <td>Calculates 5-year and lifetime invasive breast cancer risk.</td> </tr> <tr> <td class="divider_bottom" rowspan="3">Breast cancer surveillance consortium Risk <span class="nowrap_whitespace">Calculator<sup>[2]</sup></span></td> <td>Considers age, race, family history of breast cancer in a first-degree relative, breast biopsy history, and mammographic breast density.</td> </tr> <tr> <td>Does not consider family history beyond first-degree relatives with breast cancer. It does not factor in any other cancers or any paternal relatives with cancer.</td> </tr> <tr class="divider_bottom"> <td>Calculates 5- and 10-year invasive breast cancer risk.</td> </tr> <tr> <td class="divider_bottom" rowspan="6">Tyrer-Cuzick <span class="nowrap_whitespace">(IBIS)<sup>[3]</sup></span></td> <td>Considers nongenetic risk factors such as age at menarche, first term birth, biopsy history, height and weight, age at menopause, etc.</td> </tr> <tr> <td>Considers a family history of breast and ovarian cancer beyond first-degree relatives.</td> </tr> <tr> <td>Although it considers the contributions of other low-penetrance genes to breast cancer <span class="nowrap_whitespace">risk,<sup>[4]</sup></span> some evidence suggests it overestimates the risk of subsequent breast cancer, except in those with personal or family history of <em>BRCA 1/2</em> <span class="nowrap_whitespace">mutations.<sup>[5]</sup></span></td> </tr> <tr> <td>Not used in patients with a history of breast cancer.</td> </tr> <tr> <td>Often predicts breast cancer risks that are higher than other mathematic models.</td> </tr> <tr class="divider_bottom"> <td>Calculates 10-year and lifetime invasive breast cancer risk and the risk of carrying a <em>BRCA 1/2</em> mutation.</td> </tr> <tr class="divider_bottom"> <td>Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA, now called <span class="nowrap_whitespace">CanRisk)<sup>[6]</sup></span></td> <td>Considers age, BMI, alcohol consumption, number of children and age at first birth, mammographic breast density, personal cancer history, results of genetic testing (if available), and family history.</td> </tr> <tr> <td rowspan="6">BRCAPRO (part of <span class="nowrap_whitespace">CancerGene)<sup>[7]</sup></span></td> <td>Considers race, Ashkenazi Jewish ancestry, as well as extensive family history of breast, ovarian, and other cancers and constructs a pedigree.</td> </tr> <tr> <td>Considers history of oophorectomy and bilateral oophorectomy.</td> </tr> <tr> <td>Contains the Chen-Gail model, which estimates breast cancer risk on Gail model factors plus weight and mammographic density; however, this model is not well <span class="nowrap_whitespace">validated.<sup>[8]</sup></span></td> </tr> <tr> <td>Assumes that <em>BRCA 1/2</em> mutations account for all hereditary breast and ovarian <span class="nowrap_whitespace">cancers.<sup>[7,9]</sup></span></td> </tr> <tr> <td>In the highest-risk families (eg, with multiple cases of ovarian cancer and early breast cancer), the model may generate high residual risks for carrying a <em>BRCA</em> mutation (ie, the chance of carrying an undetected pathogenic variant). Thus, it may generate high risks for primary or contralateral breast cancer and ovarian cancer, even with an uninformative negative result.</td> </tr> <tr> <td>Calculates probability of having a <em>BRCA 1/2</em> mutation.</td> </tr> </tbody></table></div><div class="graphic_footnotes">DCIS: ductal carcinoma in situ; LCIS: lobular carcinoma in situ; BRCA: breast cancer susceptibility genes.</div><div class="graphic_reference">References:
<ol>
<li>Breast Cancer Risk Assessment Tool. National Cancer Institute and National Surgical Adjuvant Breast and Bowel Project. Available at: <a href="https://bcrisktool.cancer.gov/" target="_blank">www.cancer.gov/bcrisktool/</a> (Accessed on September 18, 2018).</li>
<li>Breast Cancer Surveillance Consortium Risk Calculator. Breast Cancer Surveillance Consortium. Available at: <a href="https://tools.bcsc-scc.org/BC5yearRisk/intro.htm" target="_blank">tools.bcsc-scc.org/BC5yearRisk/intro.htm</a> (Accessed on August 31, 2022).</li>
<li>IBIS Breast Cancer Risk Evaluation Tool version 8. Centre for Cancer Prevention, London. Available at: <a href="https://ems-trials.org/riskevaluator/" target="_blank">www.ems-trials.org/riskevaluator/</a> (Accessed on September 18, 2018).</li>
<li>Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004; 23:1111.</li>
<li>Mann GJ, Thorne H, Balleine RL, et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 2006; R12.</li>
<li>The CanRisk Web Tool incorporates the new version of BOADICEA v6, the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm. University of Cambridge. Available at: <a href="https://www.canrisk.org/" target="_blank">www.canrisk.org/</a> (Accessed on August 31, 2022).</li>
<li>Berry DA, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002; 20:2701.</li>
<li>Chen J, Pee D, Ayyagari R, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 2006; 98:1215.</li>
<li>Berry DA, Parmigiani G, Sanchez J, et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997; 89:227.</li>
</ol></div><div id="graphicVersion">Graphic 118958 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
